National Institute of Neurological Disorders and Stroke, 66048-66049 [2016-23143]
Download as PDF
66048
Federal Register / Vol. 81, No. 186 / Monday, September 26, 2016 / Notices
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Exclusive
Commercialization Patent License
Agreement. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: September 21, 2016.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2016–23134 Filed 9–23–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-Up
Exclusive Evaluation Patent License:
Development of Autologous Tumorreactive T Cells Isolated From
Peripheral Blood for the Treatment of
Metastatic Follicular Thyroid Cancer
and Metastatic Soft Tissue Sarcomas
National Institutes of Health.
Notice.
AGENCY:
ACTION:
The National Cancer Institute,
National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of a
Start-up Exclusive Evaluation Patent
License to MedGene Therapeutics, Inc.
(‘‘MedGene’’) located in Bethesda, MD
to practice the inventions embodied in
the patent applications listed
Supplementary Information section of
this notice.
DATES: Only written comments and/or
applications for a license which are
received by the NCI Technology
Transfer Center on or before October 11,
2016 will be considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
Start-up Exclusive Evaluation Patent
License should be directed to: Andrew
Burke, Ph.D., Licensing and Patenting
Manager, NCI Technology Transfer
Center, 9609 Medical Center Drive, RM
1E530 MSC 9702, Bethesda, MD 20892–
9702 (for business mail), Rockville, MD
20850–9702 Telephone: (240) 276–5530;
Facsimile: (240) 276–5504; Email:
andy.burke@nih.gov.
SUPPLEMENTARY INFORMATION: United
States Provisional Patent Application
mstockstill on DSK3G9T082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
19:40 Sep 23, 2016
Jkt 238001
No. 61/771,251 filed March 1, 2013,
entitled ‘‘Methods of Producing
Enriched Populations of Tumor Reactive
T Cells from Peripheral Blood’’ [HHS
Reference No. E–085–2013/0–US–01];
and PCT Application No. PCT/US2013/
038813 filed April 30, 2013 entitled
‘‘Methods of Producing Enriched
Populations of Tumor Reactive T Cells
from Peripheral Blood’’ [HHS Reference
No. E–085–2013/0–PCT–02] (and U.S.
and foreign patent applications claiming
priority to the aforementioned
applications).
The patent rights in these inventions
have been assigned to the government of
the United States of America.
The prospective Start-up Exclusive
Evaluation Patent License territory may
be worldwide and the field of use may
be limited to the development,
manufacture and commercialization of
autologous tumor-reactive peripheral
blood T cell therapy products as set
forth in the Licensed Patent Rights for
the treatment of metastatic follicular
thyroid cancer and metastatic soft tissue
sarcomas in humans.
The present invention describes a
method of selecting highly tumorreactive T cells from autologous
peripheral blood samples based on the
expression of two specific T cell surface
markers: Programmed cell death protein
1 (PD–1; CD279) and/or T cell Ig- and
mucin-domain-containing molecule-3
(TIM–3). Following selection, isolated
cells may be expanded and reinfused
into the donor patient as part of an
adoptive cell transfer therapeutic
regimen. The disclosed method may be
advantageous over existing approaches
which rely on the isolation of T cells
from tumor samples since it eliminates
the cost and complications associated
with tumor resection, as well as
provides a T cell product for patients
without resectable lesions.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective Start-up Exclusive
Evaluation Patent License will be
royalty bearing and the may be granted
unless within fifteen (15) days from the
date of this published notice, the
National Cancer Institute receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license in
the prospective field of use that are
timely filed in response to this notice
will be treated as objections to the grant
of the contemplated Start-up Exclusive
Evaluation Patent License. Comments
and objections submitted to this notice
will not be made available for public
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
inspection and, to the extent permitted
by law, will not be released under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: September 20, 2016.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2016–23048 Filed 9–23–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of an Interagency Pain
Research Coordinating Committee
(IPRCC) meeting.
The meeting will feature invited
speakers and discussions of committee
business items including a progress
report on implementation of the
National Pain Strategy, updates on the
Federal Pain Research Strategy and new
pain initiatives.
The meeting will be open to the
public and accessible by live webcast
and conference call.
Name of Committee: Interagency Pain
Research Coordinating Committee.
Type of meeting: Open Meeting.
Date: October 31, 2016.
Time: 8:30 a.m. to 5:00 p.m. *Eastern
Time*—Approximate end time.
Agenda: The meeting will feature invited
speakers and discussions of Committee
business items including a progress report on
implementation of the National Pain
Strategy, updates on the Federal Pain
Research Strategy and new pain initiatives.
Place: National Institutes of Health,
Building 31C, 6th Floor, Room 10, 31 Center
Drive, Bethesda, MD 20892.
Cost: The meeting is free and open to the
public.
Webcast Live: https://videocast.nih.gov/.
Deadlines: Notification of intent to present
oral comments: Monday, October 17, 2016,
by 5:00 p.m. ET.
Submission of written/electronic statement
for oral comments: Monday, October 24,
2016, by 5:00 p.m. ET.
Submission of written comments: Monday,
October 24, 2016, by 5:00 p.m. ET.
Access: Medical Center Metro (Red Line).
Visitor Information: https://www.nih.gov/
about/visitor/index.htm.
Contact Person: Linda L. Porter, Ph.D.,
Pain Policy Advisor, Office of Pain Policy,
Officer of the Director, National Institute of
Neurological Disorders and Stroke, NIH, 31
Center Drive, Room 8A31, Bethesda, MD
20892, Phone: (301) 451–4460, Email:
Linda.Porter@nih.gov.
E:\FR\FM\26SEN1.SGM
26SEN1
mstockstill on DSK3G9T082PROD with NOTICES
Federal Register / Vol. 81, No. 186 / Monday, September 26, 2016 / Notices
Please Note:
Any member of the public interested
in presenting oral comments to the
Committee must notify the Contact
Person listed on this notice by 5:00 p.m.
ET on Monday, October 17, 2016, with
their request to present oral comments
at the meeting. Interested individuals
and representatives of organizations
must submit a written/electronic copy
of the oral statement/comments
including a brief description of the
organization represented by 5:00 p.m.
ET on Thursday, October 24, 2016.
Statements submitted will become a
part of the public record. Only one
representative of an organization will be
allowed to present oral comments on
behalf of that organization, and
presentations will be limited to three to
five minutes per speaker, depending on
number of speakers to be accommodated
within the allotted time. Speakers will
be assigned a time to speak in the order
of the date and time when their request
to speak is received, along with the
required submission of the written/
electronic statement by the specified
deadline. If special accommodations are
needed, please email the Contact Person
listed above.
In addition, any interested person
may submit written comments to the
IPRCC prior to the meeting by sending
the comments to the Contact Person
listed on this notice by 5:00 p.m. ET,
Monday, October 24, 2016. The
comments should include the name
and, when applicable, the business or
professional affiliation of the interested
person. All written comments received
by the deadlines for both oral and
written public comments will be
provided to the IPRCC for their
consideration and will become part of
the public record.
The meeting will be open to the
public and webcast live on the Internet.
If you experience any technical
problems with the webcast, please call
the NIH IT Service Desk at (301) 496–
4357, toll free (866) 319–4357, for
webcast issues.
Individuals who participate in person
or by using the wed service and who
need special assistance, such as
captioning, should submit a request to
the Contact Person listed on this notice
at least seven days prior to the meeting.
As a part of security procedures,
attendees should be prepared to present
a photo ID during the security process
to get on the NIH campus. For a full
description, please see: https://
www.nih.gov/about/visitorsecurity.htm.
Information about the IPRCC is
available on the Web site: https://
iprcc.nih.gov/.
VerDate Sep<11>2014
19:40 Sep 23, 2016
Jkt 238001
Dated: September 20, 2016.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–23143 Filed 9–23–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
[Docket No. USCG–2010–0164]
National Boating Safety Advisory
Council
Coast Guard, DHS.
Notice of Federal Advisory
Committee meeting.
AGENCY:
ACTION:
The National Boating Safety
Advisory Council and its
Subcommittees will meet on October 20,
21 and 22, 2016, in Arlington, VA, to
discuss issues relating to recreational
boating safety. These meetings will be
open to the public.
DATES: The National Boating Safety
Advisory Council will meet on
Thursday, October 20, 2016, from 8:00
a.m. to 2:30 p.m. and on Saturday,
October 22, 2016 from 9:00 a.m. to 12:00
p.m. The Boats and Associated
Equipment Subcommittee will meet on
October 20, 2016, from 2:45 p.m. to 5:00
p.m. The Prevention through People
Subcommittee will meet on October 21,
2016, from 8:30 a.m. to 11:45 a.m. The
Recreational Boating Safety Strategic
Planning Subcommittee will meet on
October 21, 2016, from 1:00 p.m. to 5:00
p.m. Please note that these meetings
may conclude early if the National
Boating Safety Advisory Council has
completed all business.
ADDRESSES: All meetings will be held in
the Ballroom of the Holiday Inn
Arlington (https://www.hiarlington.com),
4610 N Fairfax Drive, Arlington, VA
22203.
For information on facilities or
services for individuals with disabilities
or to request special assistance at the
meeting, contact the individual listed in
the FOR FURTHER INFORMATION CONTACT
section below as soon as possible.
Instructions: To facilitate public
participation, we are inviting public
comment on the issues to be considered
by the Council as listed in the ‘‘Agenda’’
section below. Written comments for
distribution to Council members must
be submitted no later than October 1,
2016, if Council review is desired prior
to the meeting. You must include
‘‘Department of Homeland Security’’
and the docket number USCG–2010–
SUMMARY:
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
66049
0164. Written comments may also be
submitted using the Federal
eRulemaking Portal at https://
www.regulations.gov. For technical
difficulties, contact the individual listed
in the FOR FURTHER INFORMATION
CONTACT section below. Comments
received will be posted without
alteration at https://www.regulations.gov,
including any personal information
provided. You may review a Privacy Act
notice regarding the Federal Docket
Management System in the March 24,
2005, issue of the Federal Register (70
FR 15086).
Docket Search: For access to the
docket to read documents or comments
related to this notice, go to https://
www.regulations.gov insert USCG–
2010–0164 in the ‘‘Search’’ box, press
Enter, then click the item you wish to
view.
FOR FURTHER INFORMATION CONTACT: Mr.
Jeff Ludwig, Alternate Designated
Federal Officer of the National Boating
Safety Advisory Council, telephone
(202) 372–1061, or at jeffrey.a.ludwig@
uscg.mil.
Notice of
this meeting is given under the Federal
Advisory Committee Act (Title 5, U.S.C.,
Appendix). Congress established the
National Boating Safety Advisory
Council in the Federal Boat Safety Act
of 1971 (Pub. L. 92–75). The National
Boating Safety Advisory Council
currently operates under the authority
of 46 U.S.C. 13110 and 46 U.S.C.
4302(c). The latter requires the Secretary
of Homeland Security and the
Commandant of the Coast Guard by
delegation to consult with the National
Boating Safety Advisory Council in
prescribing regulations for recreational
vessels and associated equipment and
on other major safety matters.
SUPPLEMENTARY INFORMATION:
Meeting Agenda
The agenda for the National Boating
Safety Advisory Council meeting is as
follows:
Thursday, October 20, 2016
(1) Opening remarks and presentation
of awards to outgoing members.
(2) Receipt and discussion of the
following reports:
(a) Chief, Office of Auxiliary and
Boating Safety, Update on the Coast
Guard’s implementation of National
Boating Safety Advisory Council
Resolutions and Recreational Boating
Safety Program report.
(b) Alternate Designated Federal
Officer’s report concerning Council
administrative and logistical matters.
(3) Presentations on the following:
(a) Distracted Driving.
E:\FR\FM\26SEN1.SGM
26SEN1
Agencies
[Federal Register Volume 81, Number 186 (Monday, September 26, 2016)]
[Notices]
[Pages 66048-66049]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-23143]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of an Interagency Pain
Research Coordinating Committee (IPRCC) meeting.
The meeting will feature invited speakers and discussions of
committee business items including a progress report on implementation
of the National Pain Strategy, updates on the Federal Pain Research
Strategy and new pain initiatives.
The meeting will be open to the public and accessible by live
webcast and conference call.
Name of Committee: Interagency Pain Research Coordinating
Committee.
Type of meeting: Open Meeting.
Date: October 31, 2016.
Time: 8:30 a.m. to 5:00 p.m. *Eastern Time*--Approximate end
time.
Agenda: The meeting will feature invited speakers and
discussions of Committee business items including a progress report
on implementation of the National Pain Strategy, updates on the
Federal Pain Research Strategy and new pain initiatives.
Place: National Institutes of Health, Building 31C, 6th Floor,
Room 10, 31 Center Drive, Bethesda, MD 20892.
Cost: The meeting is free and open to the public.
Webcast Live: https://videocast.nih.gov/.
Deadlines: Notification of intent to present oral comments:
Monday, October 17, 2016, by 5:00 p.m. ET.
Submission of written/electronic statement for oral comments:
Monday, October 24, 2016, by 5:00 p.m. ET.
Submission of written comments: Monday, October 24, 2016, by
5:00 p.m. ET.
Access: Medical Center Metro (Red Line). Visitor Information:
https://www.nih.gov/about/visitor/index.htm.
Contact Person: Linda L. Porter, Ph.D., Pain Policy Advisor,
Office of Pain Policy, Officer of the Director, National Institute
of Neurological Disorders and Stroke, NIH, 31 Center Drive, Room
8A31, Bethesda, MD 20892, Phone: (301) 451-4460, Email:
Linda.Porter@nih.gov.
[[Page 66049]]
Please Note:
Any member of the public interested in presenting oral comments to
the Committee must notify the Contact Person listed on this notice by
5:00 p.m. ET on Monday, October 17, 2016, with their request to present
oral comments at the meeting. Interested individuals and
representatives of organizations must submit a written/electronic copy
of the oral statement/comments including a brief description of the
organization represented by 5:00 p.m. ET on Thursday, October 24, 2016.
Statements submitted will become a part of the public record. Only
one representative of an organization will be allowed to present oral
comments on behalf of that organization, and presentations will be
limited to three to five minutes per speaker, depending on number of
speakers to be accommodated within the allotted time. Speakers will be
assigned a time to speak in the order of the date and time when their
request to speak is received, along with the required submission of the
written/electronic statement by the specified deadline. If special
accommodations are needed, please email the Contact Person listed
above.
In addition, any interested person may submit written comments to
the IPRCC prior to the meeting by sending the comments to the Contact
Person listed on this notice by 5:00 p.m. ET, Monday, October 24, 2016.
The comments should include the name and, when applicable, the business
or professional affiliation of the interested person. All written
comments received by the deadlines for both oral and written public
comments will be provided to the IPRCC for their consideration and will
become part of the public record.
The meeting will be open to the public and webcast live on the
Internet. If you experience any technical problems with the webcast,
please call the NIH IT Service Desk at (301) 496-4357, toll free (866)
319-4357, for webcast issues.
Individuals who participate in person or by using the wed service
and who need special assistance, such as captioning, should submit a
request to the Contact Person listed on this notice at least seven days
prior to the meeting.
As a part of security procedures, attendees should be prepared to
present a photo ID during the security process to get on the NIH
campus. For a full description, please see: https://www.nih.gov/about/visitorsecurity.htm.
Information about the IPRCC is available on the Web site: https://iprcc.nih.gov/.
Dated: September 20, 2016.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-23143 Filed 9-23-16; 8:45 am]
BILLING CODE 4140-01-P